Ryan Haumschild, PharmD, MS, MBA, CPEL

Panelists discuss how defining and tracking meaningful real-world outcomes ensures accountability and value in MASH management.

Panelists discuss how multidisciplinary collaboration is essential for preventing progression and improving outcomes in MASH care.

Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH patients.

Panelists discuss how patients express satisfaction with digital therapeutics for their convenience and real-time accessibility, though lack of payer coverage limits the ability to gather meaningful real-world evidence on their effectiveness.

Panelists discuss how CT-155, a 16-week interactive digital application, met its primary end point in clinical trials by successfully improving experiential symptoms of schizophrenia compared with a control app, with an excellent safety profile.

Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies.

Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH care landscape.

Panelists discuss how combining effective antipsychotic medications for positive symptoms with digital therapeutics for negative symptoms could synergistically improve overall outcomes and help young patients achieve their life goals.

Panelists discuss how prescription digital therapeutics can expand access to specialized mental health interventions in underserved rural communities where traditional therapy resources are scarce or unavailable.

Panelists discuss how GLP-1 therapies show dual metabolic and hepatic benefits, redefining MASH management.

Panelists discuss how recognizing high-risk patients and linking liver care with metabolic management can reduce both disease and economic impact.

Panelists discuss how evolving policy reforms will reshape oncology research by balancing innovation, access, and affordability.

Panelists discuss how IRA-driven BTK inhibitor price changes could shift payer preferences, necessitating vigilance to preserve clinical integrity in treatment selection.

Panelists discuss how the IRA’s drug pricing reforms aim to improve affordability but may influence future oncology innovation.

Panelists discuss how integrating safety and access considerations into oncology policy can create more equitable, patient-centered coverage models.

Panelists discuss how utilization management limits clinical autonomy and advocate for reforms that preserve shared, patient-centered decision-making.

Panelists discuss how payers should interpret black box warnings with clinical context to prevent unnecessary restrictions on safe, evidence-based treatments.

Panelists discuss how integrating real-world evidence into coverage frameworks can enhance decision-making and align payer policies with actual patient outcomes.

Panelists discuss how outdated coverage decisions can worsen outcomes and increase costs by delaying access to safer, evidence-supported BTK inhibitor therapies.

Panelists discuss how payer coverage restrictions often conflict with NCCN guidelines for BTK inhibitor therapies in CLL, impeding evidence-based care.

Panelists discuss how outdated coverage models lag behind oncology innovation, calling for dynamic policies that reflect evolving clinical evidence.

Panelists discuss how step edits hinder timely cancer treatment and urge policies that prioritize evidence-based access over cost-driven sequencing.

Panelists discuss how utilization management policies can delay oncology care and call for reforms that better align oversight with clinical evidence.

Panelists discuss how PBMs shape oncology access and stress the need for transparency to align financial control with clinical priorities.

Panelists discuss how digital therapeutics could address the enormous unmet need for treating negative symptoms in the 60% of patients with schizophrenia who experience them, potentially reducing health care costs and improving quality of life.

Panelists discuss how prescription digital therapeutics like Daylight show promise for treating depression and anxiety but face significant accessibility barriers due to lack of payer coverage and high out-of-pocket costs.

Panelists discuss how structured, multidisciplinary screening efforts can catch MASH earlier and prevent progression.

Panelists discuss how metabolic dysfunction drives liver injury, highlighting early recognition of the obesity–MASH connection as key to prevention.

Panelists discuss how aligning evolving payer policies with real-world oncology practice is key to sustaining timely and equitable patient access.

Panelists discuss how national policy reforms are reshaping oncology care by balancing affordability efforts with the need to preserve access and innovation.